Other therapy.
FOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreI-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read MoreBudget impact analysis for the Health Care Package by using MammaPrint in Belgium
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Read More
Durvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MoreGene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer
PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Read More
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC
Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
Publication: St Gallen Authors: M. Kleijn, J. McKelley, Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Read More
Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients
PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Read More
